A review by krisko6 (740). After 13 years, Half-Life has returned

In between topics to rant about, I thought I would tell you a little bit more about what it's like to be a biotech scientist. I've been in many different sized biotechs and even between them, the culture can vary quite a bit. Therefore, I'll try and describe it in general terms to give you an overview of the life of an industry scientist in research and development (R&D). Of course, some people wi; (read more)

Source: Suzy - Discipline: BioTech

As more and more of my academic scientist friends become disillusioned with their prospects for a balanced life or financial freedom, moving to industry seems the logical choice. If you really want to make the big dollars, you'll want to move out of the lab and try out marketing or sales. Now, you won't be able to go directly to a marketing position from the lab without some marketing experience o; (read more)

Source: Suzy - Discipline: BioTech

I am a scientist for profit. This means, as you are well aware, I have to work with marketing people to generate pretty pictures showing perfect results with any product that we sell. You know those flyers and brochures and ads in BioTechniques where a tiny picture of a gel or a qPCR assay with photoshop perfect curves or bands is plopped on the page next to some meaningless picture and supposed t; (read more)

Source: Suzy - Discipline: BioTech

I would like to thank AGreenMonster for these great questions for discussion. I am going to answer these from my perspective, which is from a life science company. I welcome anyone to give their feedback as well. In fact, if any of the readers out there feels like they have a lot to share, I would be happy to host your article on my blog so that you may provide more details. Just drop me a line.Hi; (read more)

Source: Suzy - Discipline: BioTech

My travel schedule is set for another year. Every year I tell myself I’m not going to commit to so much travel but whenever I am asked to cover some event, it’s an opportunity for me to talk to people in diverse and burgeoning fields and get new ideas for products, so I don’t say no.  And who doesn’t enjoy attending conferences? So I’ll be traveling to a conference every month from no; (read more)

Source: Suzy - Discipline: BioTech

I thought long and hard about the blog topic today because really, when you think about the subject of "what would I be doing now, if I could be doing something else" well, that's a complicated question.There's the thing you could have been doing if you had chosen a completely different path a long, long time ago. That's totally different from what I would; (read more)

Source: Suzy - Discipline: Research

 Last week the biotech community in San Diego suffered a tough blow as many positions were eliminated as part of a plan to save $20 million dollars in the hopes that Life Tech will please their investors.  People who lost jobs included veterans with the company, many who were loyal and hard-working to the almighty borg of biotechs, sacrificing their nights, vacations, and weekend; (read more)

Source: Suzy - Discipline: BioTech

“Even after weeks of staying home, my kids are just not interested in all the stuff we have. Let’s be honest. If a toy isn’t getting any action amid this distraction-free, stuck-at-home living, chances are it’s never getting touched again.” Liz Russell figures out what really engages and changes kids during the quarantine, and will […]

“The most difficult part was persuading our children that they had the freedom to make anything they wanted,” writes mom Anam Ahmed at Let Grow. (Click here!) …Like most kids, my children live prescheduled lives (at least they did in “the time before”). At school, someone tells them when to play outside and when to […]

“When I was 17, I was in a serious accident and had to be home for months. Looking out at our boring backyard, I daydreamed a plan for my life. It became a blueprint.” So writes Holly Korbey in a lovely piece at Let Grow. There are different kinds of daydreaming, of course, and some don’t […]

We previously established that global deletion of the enhancer of trithorax and polycomb (ETP) gene, Asxl2, prevents weight gain. Because proinflammatory macrophages recruited to adipose tissue are central to the metabolic complications of obesity, we explored the role of ASXL2 in myeloid lineage cells. Unexpectedly, mice without Asxl2 only in myeloid cells (Asxl2ΔLysM) were completely resistant to diet-induced weight gain and metabolically normal despite increased food intake, comparable activity, and equivalent fecal fat. Asxl2ΔLysM mice resisted HFD-induced adipose tissue macrophage infiltration and inflammatory cytokine gene expression. Energy expenditure and brown adipose tissue metabolism in Asxl2ΔLysM mice were protected from the suppressive effects of HFD, a phenomenon associated with relatively increased catecholamines likely due to their suppressed degradation by macrophages. White adipose tissue of HFD-fed Asxl2ΔLysM mice also exhibited none of the pathological remodeling extant in their control counterparts. Suppression of macrophage Asxl2 expression, via nanoparticle-based siRNA delivery, prevented HFD-induced obesity. Thus, ASXL2 controlled the response of macrophages to dietary factors to regulate metabolic homeostasis, suggesting modulation of the cells’ inflammatory phenotype may impact obesity and its complications.

Arterial cardiovascular events are the leading cause of death in patients with JAK2V617F myeloproliferative neoplasms (MPNs). However, their mechanisms are poorly understood. The high prevalence of myocardial infarction without significant coronary stenosis or atherosclerosis in patients with MPNs suggests that vascular function is altered. The consequences of JAK2V617F mutation on vascular reactivity are unknown. We observe here increased responses to vasoconstrictors in arteries from Jak2V617F mice resulting from a disturbed endothelial NO pathway and increased endothelial oxidative stress. This response was reproduced in WT mice by circulating microvesicles isolated from patients carrying JAK2V617F and by erythrocyte-derived microvesicles from transgenic mice. Microvesicles of other cellular origins had no effect. This effect was observed ex vivo on isolated aortas, but also in vivo on femoral arteries. Proteomic analysis of microvesicles derived from JAK2V617F erythrocytes identified increased expression of myeloperoxidase as the likely mechanism accounting for their effect. Myeloperoxidase inhibition in microvesicles derived from JAK2V617F erythrocytes suppressed their effect on oxidative stress. Antioxidants such as simvastatin and N-acetyl cysteine improved arterial dysfunction in Jak2V617F mice. In conclusion, JAK2V617F MPNs are characterized by exacerbated vasoconstrictor responses resulting from increased endothelial oxidative stress caused by circulating erythrocyte-derived microvesicles. Simvastatin appears to be a promising therapeutic strategy in this setting.

Tumor-associated peptide–human leukocyte antigen complexes (pHLAs) represent the largest pool of cell surface–expressed cancer-specific epitopes, making them attractive targets for cancer therapies. Soluble bispecific molecules that incorporate an anti-CD3 effector function are being developed to redirect T cells against these targets using 2 different approaches. The first achieves pHLA recognition via affinity-enhanced versions of natural TCRs (e.g., immune-mobilizing monoclonal T cell receptors against cancer [ImmTAC] molecules), whereas the second harnesses an antibody-based format (TCR-mimic antibodies). For both classes of reagent, target specificity is vital, considering the vast universe of potential pHLA molecules that can be presented on healthy cells. Here, we made use of structural, biochemical, and computational approaches to investigate the molecular rules underpinning the reactivity patterns of pHLA-targeting bispecifics. We demonstrate that affinity-enhanced TCRs engage pHLA using a comparatively broad and balanced energetic footprint, with interactions distributed over several HLA and peptide side chains. As ImmTAC molecules, these TCRs also retained a greater degree of pHLA selectivity, with less off-target activity in cellular assays. Conversely, TCR-mimic antibodies tended to exhibit binding modes focused more toward hot spots on the HLA surface and exhibited a greater degree of crossreactivity. Our findings extend our understanding of the basic principles that underpin pHLA selectivity and exemplify a number of molecular approaches that can be used to probe the specificity of pHLA-targeting molecules, aiding the development of future reagents.

BACKGROUND Neurofibroma/schwannoma hybrid nerve sheath tumors (N/S HNSTs) are neoplasms associated with larger nerves that occur sporadically and in the context of schwannomatosis or neurofibromatosis type 2 or 1. Clinical management of N/S HNSTs is challenging, especially for large tumors, and established systemic treatments are lacking.METHODS We used next-generation sequencing and array-based DNA methylation profiling to determine the clinically actionable genomic and epigenomic landscapes of N/S HNSTs.RESULTS Whole-exome sequencing within a precision oncology program identified an activating mutation (p.Asp769Tyr) in the catalytic domain of the ERBB2 receptor tyrosine kinase in a patient with schwannomatosis-associated N/S HNST, and targeted treatment with the small-molecule ERBB inhibitor lapatinib led to prolonged clinical benefit and a lasting radiographic and metabolic response. Analysis of a multicenter validation cohort revealed recurrent ERBB2 mutations (p.Leu755Ser, p.Asp769Tyr, p.Val777Leu) in N/S HNSTs occurring in patients who met diagnostic criteria for sporadic schwannomatosis (3 of 7 patients), but not in N/S HNSTs arising in the context of neurofibromatosis (6 patients) or outside a tumor syndrome (1 patient), and showed that ERBB2-mutant N/S HNSTs cluster in a distinct subgroup of peripheral nerve sheath tumors based on genome-wide DNA methylation patterns.CONCLUSION These findings uncover a key biological feature of N/S HNSTs that may have important diagnostic and therapeutic implications.FUNDING This work was supported by grant H021 from DKFZ-HIPO, the University Cancer Center Frankfurt, and the Frankfurt Research Funding Clinician Scientist Program.

BACKGROUND Preclinical experiments have shown that donor blood cells, modified in vitro by an alkylating agent (modified immune cells [MICs]), induced long-term specific immunosuppression against the allogeneic donor.METHODS In this phase I trial, patients received either 1.5 × 106 MICs per kg BW on day –2 (n = 3, group A), or 1.5 × 108 MICs per kg BW on day –2 (n = 3, group B) or day –7 (n = 4, group C) before living donor kidney transplantation in addition to post-transplantation immunosuppression. The primary outcome measure was the frequency of adverse events (AEs) until day 30 (study phase) with follow-up out to day 360.RESULTS MIC infusions were extremely well tolerated. During the study phase, 10 treated patients experienced a total of 69 AEs that were unlikely to be related or not related to MIC infusion. No donor-specific human leukocyte antigen Abs or rejection episodes were noted, even though the patients received up to 1.3 × 1010 donor mononuclear cells before transplantation. Group C patients with low immunosuppression during follow-up showed no in vitro reactivity against stimulatory donor blood cells on day 360, whereas reactivity against third-party cells was still preserved. Frequencies of CD19+CD24hiCD38hi transitional B lymphocytes (Bregs) increased from a median of 6% before MIC infusion to 20% on day 180, which was 19- and 68-fold higher, respectively, than in 2 independent cohorts of transplanted controls. The majority of Bregs produced the immunosuppressive cytokine IL-10. MIC-treated patients showed the Immune Tolerance Network operational tolerance signature.CONCLUSION MIC administration was safe and could be a future tool for the targeted induction of tolerogenic Bregs.TRIAL REGISTRATION EudraCT number: 2014-002086-30; ClinicalTrials.gov identifier: NCT02560220FUNDING Federal Ministry for Economic Affairs and Technology, Berlin, Germany, and TolerogenixX GmbH, Heidelberg, Germany.

Colitis caused by Clostridium difficile infection is a growing cause of human morbidity and mortality, especially after antibiotic use in health care settings. The natural immunity of newborn infants and protective host immune mediators against C. difficile infection are not fully understood, with data suggesting that inflammation can be either protective or pathogenic. Here, we show an essential role for IL-17A produced by γδ T cells in host defense against C. difficile infection. Fecal extracts from children with C. difficile infection showed increased IL-17A and T cell receptor γ chain expression, and IL-17 production by intestinal γδ T cells was efficiently induced after infection in mice. C. difficile–induced tissue inflammation and mortality were markedly increased in mice deficient in IL-17A or γδ T cells. Neonatal mice, with naturally expanded RORγt+ γδ T cells poised for IL-17 production were resistant to C. difficile infection, whereas elimination of γδ T cells or IL-17A each efficiently overturned neonatal resistance against infection. These results reveal an expanded role for IL-17–producing γδ T cells in neonatal host defense against infection and provide a mechanistic explanation for the clinically observed resistance of infants to C. difficile colitis.

Hypoxia-inducible factor (HIF) is strikingly upregulated in many types of cancer, and there is great interest in applying inhibitors of HIF as anticancer therapeutics. The most advanced of these are small molecules that target the HIF-2 isoform through binding the PAS-B domain of HIF-2α. These molecules are undergoing clinical trials with promising results in renal and other cancers where HIF-2 is considered to be driving growth. Nevertheless, a central question remains as to whether such inhibitors affect physiological responses to hypoxia at relevant doses. Here, we show that pharmacological HIF-2α inhibition with PT2385, at doses similar to those reported to inhibit tumor growth, rapidly impaired ventilatory responses to hypoxia, abrogating both ventilatory acclimatization and carotid body cell proliferative responses to sustained hypoxia. Mice carrying a HIF-2α PAS-B S305M mutation that disrupts PT2385 binding, but not dimerization with HIF-1β, did not respond to PT2385, indicating that these effects are on-target. Furthermore, the finding of a hypomorphic ventilatory phenotype in untreated HIF-2α S305M mutant mice suggests a function for the HIF-2α PAS-B domain beyond heterodimerization with HIF-1β. Although PT2385 was well tolerated, the findings indicate the need for caution in patients who are dependent on hypoxic ventilatory drive.

This isn’t in the photos, but it’s foggy and cold this morning in western Washington. It’s the weirdest summer I’ve ever experienced — foggy, frigid mornings, cool days, and then freezing nights! It’s not very pleasant for a desert creature like myself, but it’s quite nice to sit inside and write in my blog a least. I have to say, it sure is weird, though. It’s August and I wear a sweater or sweatshirt most of the time and then I’m still cold! ^^; There are a few sunny days here and there, though. I get out on those days, into the wilderness and bright blue beyond. Sometimes, I just drive and drive in my still-unnamed yellow bug, and other times I find something that not a lot of people know about. This is about one of them. ^^ I love to wander, to find all of the nooks and crannies of wherever I happen to be. Tourist sites? Well, they’re usually cool and I want to see them, but it’s the little, hidden things off the beaten trail that really get my soul revving. So, Johns River (no apostrophe, it was named back when apostrophes weren’t used on maps) was one of those things. I found out about it by googling and googling, thinking that someone, somewhere, must have written about something other than the two really traveled trails in Grays Harbor. I mean, this area is the gateway to the wild peninsula of Washington, where according to Stephanie Meyer and Patricia Briggs, vampires and werewolves run wild. I also loooooooove mountain meadows. Johns river is not in the mountains, so I suppose that it mostly qualifies as grassland surrounded by trees? It’s just a little concrete path, and it’s not even a mile (0.6 miles one way) long, but with the river on one side and a huge expanse of pasture to the other side, it took my breath away.   Just look at this. Elk supposedly graze around here a lot, and I didn’t see any since I went during midday, but I bet it’s really a sight at sunset. It’s not far, so I will definitely have to come back. Can’t you just imagine little river sprites lounging on the bank, cleaning themselves? And little fairies flitting through the air? I bet this is a really magical place at sunset.   The little shack in the distance is off the trail. It’s supposedly for hunters (YUCK) and photographers. It would make a wonderful place to watch the sprites from. This shack is at the very end of the trail, and the same thing. It’s boring inside. I didn’t see any geldings, but I saw a few mosquitoes and a spider. If you’re lucky enough to have a horse that loves to take you along on its adventures, you can continue. I was wearing shorts, so I didn’t go, because ticks! But I will come back. Yes, I will come back. :3 Road to nowhere. Ignore the buildings. They’re only there for magical curse removal. Here’s a panorama of wildness. I’m feeling really magical today, can’t you tell? I think it’s because I have Daniel Waples playing in the background, and it’s all foggy outside. That reminds me that I want a handpan so badly. I need to find a handpan that I can afford soooooo badly, because I think it’s a music that speaks to my inner essence. Does anyone know what these gorgeous purple flowers are? They’re not lavender. The River People watch over this creek. Be careful to please them. It’s me. Sometimes I wear bright colors, sometimes I wear pastels. I don’t think that a magical being has to stick to  neutrals. (That hand thing is a shaka, a very cool gesture that I learned during my time in Hawaii that means “hang loose.” I like to think that it also means that you should be yourself and follow your instincts.) I think that I’ll go research handpans again. I should write down how much they cost so that I can be sure to stock my Airstream with one when I get it. ???? Here’s to the future! Excelsior! (Is that a good “to infinity, and beyond!!” kind of quote? If not, what should I use instead? I feel like “banzai!” is overused) Oh, and I’ve been arting on my Tumblr lately. I’ve been writing a serial ficiton that is mysterious connected to my soon-to-come comic, Denkiki on my other tumblr. Go check them out!  I’m going to start using my mailing list soon, too, to keep people updated, so stay tuned and I’ll post the link soon! Or make it a popup, I’m not sure. But I want to offer something cool for when people sign up. ???? Chaoness!

It’s release day for my new MM romance! My last release was Christmas 2018, so I’m very excited to finally have a new book for you. When I was in Australia earlier this year, I got hooked on Bondi Rescue, and this (completely fictional!) romance between a trainee and an older, very closeted lifeguard was born. […]

A new NFC specification announced this week by the NFC Froum will allow future NFC enabled devices to offer wireless charging capabilities, which means a smartphone could be used to charge a small accessory like headphones.


According to the NFC Forum, the Wireless Charging Specification (WLC) will allow smartphones or other NFC charging devices to wirelessly charge small, battery-powered consumer and IoT devices at a power transfer rate of up to one watt.

The 1W rating is much slower than the Qi-based standard used by iPhones and other smartphones. Qi-based wireless charging on the iPhone maxes out at 7.5W, but is even faster on some Android devices.

Charging over NFC would require new hardware, and it's not a feature that can be added to existing devices. The NFC Forum believes the WLC specification could be used to complement Qi-based wireless charging.

It works using a single antenna to manage communications and charging, which is convenient for low-power devices like smart watches, fitness trackers, and earbuds that already use NFC for connectivity because there's no need to build in Qi support.

"The NFC Forum's Wireless Charging Technical Specification allows for wireless charging of small battery-powered devices like those found in many of the estimated 36 billion IoT devices in use today," said Koichi Tagawa, chair, NFC Forum. "NFC wireless charging is truly transformative because it changes the way we design and interact with small, battery-powered devices as the elimination of plugs and cords enables the creation of smaller, hermetically-sealed devices."

Apple in 2015 joined the NFC Forum and participates in the approval of new NFC specifications and developments.

Rumors in 2019 suggested that Apple was working on bilateral wireless charging that would allow its iPhones to charge the AirPods and the Apple Watch, but the feature was ultimately nixed. At the time, Apple analyst Ming-Chi Kuo said that the two-way wireless charging feature Apple was exploring did not meet Apple's requirements.

Samsung has implemented bilateral wireless charging in its smartphones, but the Wireless PowerShare option does not use NFC and is powered by the Qi-based charging coils in the device. Samsung's smartphones can charge other smartphones or accessories like headphones that support Qi wireless chargers.
This article, "New NFC Specification Will Let Smartphones Charge Small Devices" first appeared on MacRumors.com

Discuss this article in our forums

Erowid Exp101191

The response of Senator Richard Blumenthal to my letter in opposition to the Trans-Pacific Partnership (TPP). Ask yourselves how American labor can compete against Vietnamese workers earning on average $0.56 per hour. Continue reading →

The Senate considered H.R. 1314, the legislative vehicle for trade promotion authority reauthorization.?It would give the president broad fast-track authority when negotiating trade agreements and require Congress to consider treaties without an amendment process. Senator Bernie Sanders speaks out against this bill before the Senate on May 12, 2015. Continue reading →

Bernie Sanders calls out Hillary Clinton to announce her position on the Trans-Pacific Partnership (TPP) agreement; however, Hillary Clinton refuses to reveal her position, hoping that the agreement will be passed and she won't have to take a position. Continue reading →

"This is supposed to be a political party. In a healthy society, there would be a democratic process in the Democratic Party, by which elected people would be overseeing these issues by making sure there wasn’t just nepotism and insider dealing," Curry says. "That the political party itself — which is supposed to be the progressive party — has become mortgaged to a small group of Washington insiders, who raise money from large corporate PACs, [and] has become just a dead carcass of what it once was, is the most important piece of information that this contretemps over the data files has emphasized. It’s time for progressives in this country to stand up and demand a genuinely democratic process." Continue reading →

'Lesser of Two Evils' argument is not resonating with DNC protestors. Salon.com's Ben Norton says grassroots movements will be more mobilized under a Republican candidacy. "There?s no question that Trump would be horrific as a candidate but if we have 4 or 8 years of Clinton of more wars, of more austerity, of another economic crisis, and potential bailouts of banks and large corporations etc., you know you think Trump is bad now? Wait for what we'?ll see in 4 or 8 years." Continue reading →

"And you know, we have to stop looking beyond this election cycle and see that this corporate driven ideology, you know, this commodification of the culture, this constant extracting of blood from us as citizens to pay what in essence were private debts of the banks which engaged in casino capitalism, has political consequences. History has taught us that. And Hillary Clinton is only going to further that process." Continue reading →

I remember reading somewhere that if the earth was shrunk to the size of a pool ball, or a pool ball expanded to the size of the earth, the earth would be the smoother of the two.

captured camera lens focal length aperture shutter speed shooting mode exposure bias metering mode ISO flash image quality RAW converter image editor plugins (etc) cropped?

4.10pm on 7/4/16 Fujifilm X-T1 XF 10-24mm f/4 R OIS 14.5mm f/5.6 1/125 aperture priority 0.7 average 200 no RAW Camera Raw Photoshop CC (2014) none 2x1 (& stretched a bit)

ENGIE, a global leader in energy transition, today announced a new initiative with IBM. This nonexclusive, technological and commercial alliance is designed to improve the management of cities by looking at patterns, event correlation, anomaly detection and real-time data across all parts of cities.

Each year, weather-related power outages cost the U.S. economy as much as $33 billion a year. Additionally, one severe weather event has the potential to impact the daily lives and routines of millions of people. As 2017 marks the fifth anniversary of Superstorm Sandy, The Weather Company, an IBM Business (NYSE: IBM) and Zpryme are releasing the results of a survey that found that U.S. utility companies still feel underprepared for weather-related outages and that their reactive approach to outage prediction leads to lost time and resources.

The critical media debate over easing the COVID-19 lockdown. Why we must not minimise the dangers.

IBM and the University of California San Diego have announced a multi-year project to enhance quality of life and independence for aging populations through the new Artificial Intelligence for Healthy Living Center (AIHL), located on the campus of UC San Diego. The groundbreaking center will bring together the technology, artificial intelligence and life sciences knowledge of IBM and UC San Diego to promote critical research and applications in two thematic areas: Healthy Aging and the Human Microbiome.

IBM and MIT today announced that IBM plans to make a 10-year, $240 million investment to create the MIT–IBM Watson AI Lab in partnership with MIT. The lab will carry out fundamental artificial intelligence (AI) research and seek to propel scientific breakthroughs that unlock the potential of AI. The collaboration aims to advance AI hardware, software and algorithms related to deep learning and other areas, increase AI’s impact on industries, such as health care and cybersecurity, and explore the economic and ethical implications of AI on society. IBM’s $240 million investment in the lab will support research by IBM and MIT scientists.

1-800-Flowers.com, Inc. (NASDAQ: FLWS) Gifts When you Need, an online gift concierge for the leading provider of floral and gourmet gifts, may help shoppers uncover the perfect gift for Moms this year. Data from thousands of customers using GWYN powered by IBM Watson (NYSE: IBM) gives insight on hot gifts picks for Mother’s Day.

One morning at the tidepools and chance upon the largest creature on earth.

IBM today announced it is building an industry-first insurance platform on the IBM Cloud that aims to improve the processes and economics for new product development, underwriting, and benefits delivery.

Mayo Clinic and IBM Watson Health today unveiled results from early use of the Watson for Clinical Trial Matching, an IBM cognitive computing system. Use of this system in the Mayo Clinic oncology practice has been associated with more patients enrolled in Mayo’s breast cancer clinical trials.

IBM today announced a new data protection software that is easy to set up, easy to manage and helps simplify data recovery. IBM Spectrum Protect™Plus can be set up quickly making data protection available in as little as one hour.

IBM today unveiled its next-generation Power Systems Servers incorporating its newly designed POWER9 processor. Built specifically for compute-intensive AI workloads, the new POWER9 systems are capable of improving the training times of deep learning frameworks by nearly 4x allowing enterprises to build more accurate AI applications, faster.